
TORONTO, April 17 /CNW/ - The Special Committee of Independent Directors of Patheon Inc. ("Patheon") (TSX:PTI) today announced that the Ontario Securities Commission (the "OSC") has ordered JLL Patheon Holdings LLC ("JLL") to revise its unsolicited offer (the "Offer") to acquire any and all of the restricted voting shares (the "Restricted Voting Shares") of Patheon and to take certain other steps before JLL can proceed with its Offer.
The revisions and other steps the OSC has required JLL to take, which are described in more detail below, are intended to ensure equal treatment of Patheon shareholders and include the termination of JLL's side deal with a group of shareholders (the "MOVA Group"), led by Joaquin Viso, and an extension of the Offer.
The Special Committee is gratified that the OSC took steps to remedy the structural and process concerns regarding the JLL Offer, including the unequal treatment of shareholders, raised by the Special Committee and numerous shareholders. The Special Committee continues to have confidence in the long-term prospects of Patheon, which all shareholders can enjoy by rejecting the opportunistic JLL Offer.
Under the order issued yesterday by the OSC, JLL must satisfy the
following conditions in order for it to proceed with its Offer:
- JLL's side deal with the MOVA Group will be terminated;
- JLL will provide a certification to the effect that no oral or
written agreement, arrangement or understanding, formal or informal,
direct or indirect, currently exists or will be entered into or
agreed to during the Offer and for a period of 120 days following its
expiry with any shareholder (including the MOVA Group) of Patheon in
respect of the Offer or any second-step transaction, or Patheon or
any of its securities, including the acquisition or voting thereof,
other than in connection with a second-step transaction in which all
shareholders are to receive the same consideration as the
consideration under the Offer or all shareholders tendering to the
Offer receive the same consideration as that paid to shareholders in
the second-step transaction;
- The MOVA Group will provide a similar certification with regard to
JLL;
- JLL will make amendments to its Offer circular, and will issue a news
release to make full disclosure of the terms of the OSC's decision
and of any consequential changes resulting from it; and
- JLL will extend the Offer for a period of at least 15 days following
the mailing of a notice of variation in respect of these amendments.
The OSC made this order following the completion of the previously announced OSC proceedings arising from the Special Committee's application challenging the legality of the Offer. The OSC decision dismisses the application, provided that the above conditions are satisfied. The OSC provided oral reasons and said that it had not yet determined whether it will issue written reasons.
As previously announced, in the course of discussions with OSC staff in connection with these proceedings, JLL agreed that the side deal with the MOVA Group would be terminated. Accordingly, the OSC did not make an express ruling on the legality of that agreement. In its oral reasons, the OSC said that it had the authority to cease trade the Offer, but did not propose to do so because of a proposal made by JLL to avoid a hearing by accepting certain conditions. The OSC also stated that, in the context of its consideration of the exemptive relief application made by JLL, it had concerns with respect to the Offer as it related to the equal treatment of shareholders. OSC staff made submissions at the hearing in support of the positions of the Special Committee.
The Special Committee believes that the result of the OSC proceedings vindicates its view that JLL was not treating all shareholders equally and that the agreement with the MOVA Group violated Ontario's securities laws. As a result of the OSC's order, if JLL is to pursue the Offer, it will be unable to continue to provide unequal treatment to shareholders either in the Offer or in a second-step transaction effected within 120 days.
If JLL continues to pursue the Offer, the earliest date on which the Offer could expire would be May 2, 2009 (if JLL were to mail a notice of variation complying with the OSC conditions on April 17). Accordingly shareholders need take no action with regard to the Offer at this time.
As previously announced, the Board of Directors of Patheon has determined that, based on the unanimous recommendation of the Special Committee, the Offer is INADEQUATE and advises holders of Restricted Voting Shares of Patheon to NOT TENDER their shares to the Offer. BMO Capital Markets has delivered an independent valuation to the Special Committee indicating that, as of February 16, 2009, the fair value of the Restricted Voting Shares is in the range of US4.20 to US$5.00.
The Special Committee believes that Patheon remaining an independent company and executing its business plan can permit Shareholders to realize substantial value, well in excess of the Offer, by retaining their investment in the Company and benefitting from the realization of Patheon's potential. The Special Committee also believes that an important element of the achievement of this goal is that Patheon have a Board of Directors that includes a majority of independent directors.
Shareholders who have tendered their Restricted Voting Shares to the Offer and wish to obtain advice or assistance in withdrawing their shares should contact their broker or Kingsdale Shareholder Services Inc., Patheon's information agent, at the phone number below.
ABOUT PATHEON
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.
Patheon's integrated development and manufacturing network of 11 facilities, and 6 development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.
Caution Concerning Forward-Looking Statements
This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.
%SEDAR: 00001700E